Current TKI Therapy Practices and TKI Combinations in Lung Cancer
James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses current practices for administering TKI therapy and the potential for TKI combinations.
James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses current practices for administering TKI therapy and the potential for TKI combinations.
Clinical Pearls:
- Physicians should test for EGFR and ALK mutations in all non-squamous-non-small cell lung cancer patients who have metastatic disease.
- Patients who have any of these mutations will be treated with TKI monotherapy.
- There are strategies to combine TKIs with bevacizumab or chemotherapy in the experimental setting.
- Patients who have developed resistance, the current standard is to receive chemotherapy.
- In the experimental setting, researchers are exploring EGFR TKIs in combination with targeted therapies or ALK inhibitors for patients who have developed resistance.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
